News >

Biosimilar Education Critical to Accelerating Integration Into Standard Oncology Practice

Gina Columbus @ginacolumbusonc
Published: Thursday, Aug 29, 2019

Robert M. Rifkin, MD, FACP, medical oncology/hematology at Rocky Mountain Cancer Centers of The US Oncology Network

Robert M. Rifkin, MD, FACP

The mission of utilizing biosimilars in oncology is to increase access to therapeutic agents while decreasing costs, but education on this class of drugs will be imperative in seeing this through, explained Robert M. Rifkin, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x